Simbionix USA Corp. acquired the Arthro VR arthroscopic training simulator line from Spain’s GMV for an undisclosed amount.
The deal broadens Simbionix’s footprint in the orthopedic training arena. The Arthro VR features a line of simulated procedures using fiberglass limb replicas, 3D images and haptic sensation.
"Identified by Simbionix as a leading product line in a growing field, the Arthro VR is a well suited addition to our current line of industry leading simulators and integrates nicely with our global distribution channel," Simbionix CEO Gary Zamler said in prepared remarks. "This purchase demonstrates our ongoing commitment to advancing medical education, and identifying high quality simulation technologies for our expanding global customer base. Simbionix will continue to invest resources in arthroscopy, enhancing available modules and growing the simulator lines capabilities. I would also like to express our appreciation to the GMV Management team for the cooperative spirit and manner in which we worked together so well over the past few months, leading to this desirable result."
Sign up to get our free newsletters delivered right to your inbox
GPOs: Premier, Novation ink new deals
Group purchasing organizations Premier and Novation inked new deals for blunt cannula access devices, contrast media and vascular access products.
Premier said it signed a deal with Becton, Dickinson (NYSE:BDX) for for blunt cannula access devices and contracted for contrast media with Bayer HealthCare (PINK:BAYRY), Bracco Diagnostics, Lantheus Medical Imaging, Covidien’s (NYSE:COV) Mallinckrodt subsidiary and Medrad.
Novation said its deals for vascular access products were struck with AngioDynamics (NSDQ:ANGO), Arrow International, C.R. Bard (NYSE:BCR), Covidien and Medical Components Inc.
Medquist rebrands as M*Modal
MedQuist Holdings (NSDQ:MODL) said it’s unifying its advanced speech and language understanding technologies, medical transcription, coding, HIM professional services and analytics offerings under the M*Modal brand. Shares of the company’s common stock began trading on the NASDAQ exchange under the MODL symbol Jan. 25. Read more
Essilor inks China, Europe deals, adding nearly $45M to its top line
Essilor (EPA:EI) said it inked a pair of new deals representing roughly €22 million (~$29.1 million) in additional revenues.
The French ophthalmic device maker said it bought a majority interest in Jiangsu Youli Optics Co. Ltd., a manufacturer of ophthalmic lenses in Danyang that generates annual sales of roughly €15 million (~$19.8 million). Essilor also acquired a majority stake in another lens manufacturer, Jiangsu Seeworld Optical Co. Ltd., with annual revenues of nearly €7 million (~$9.3 million).
In Europe, Essilor bought a majority holding in Reize, a Swiss ophthalmic products distributor that generates about €11 million (~$14.5 million) in annual revenues. Read more
PPD, VirtualScopics expand alliance
Pharmaceutical Product Development Inc. and VirtualScopics (NSDQ:VSCP) expanded their 1-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to include oncology, central nervous system, cardiovascular, general medicine and medical devices. Read more
